This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Well Characterized Biologics & Biological Assays

Savings Deadline Ends In:

  • 00
  • 00
  • 00
  • 00
November 1-3, 2022
College Park Marriott Hotel & Conference CenterHyattsville, Maryland, USA

Kevin Zen, PhD
Executive Director, CMC at AnaptysBio


I have been responsible for overseeing biologics development: Biologics CMC and Technical Operations (from cell line development to fill finish) and overseen external contract development and manufacturing organizations (CDMO). Prior to the current position at AnaptysBio, I held leadership positions at Allergan, Allgenesis, AstraZeneca, Becton Dickinson, and Catalent Pharma Solutions/Cardinal Health PTS where I had managed cGMP operations, cell line development, bioprocess development, DS manufacture and fill, DS/DP formulation, protein analytical, primary and secondary structural elucidation, higher order structure characterization, QC release/stability, and technology transfer for sterile, parenteral DP fill/finish for clinical supply and commercial products. I obtained my PhD in Biomedical Sciences from the Mount Sinai School of Medicine (NYU) in New York City and did my postdoctoral research in the laboratory of Ronald Kaback (a member of National Academy of Sciences) at the Howard Hughes Medical Institute in Los Angeles.

Agenda Sessions

  • Analytical Technologies and CMC Comparability of Biotechnology Products


Speakers at this event